Tumor microenvironment parameters as a predictor of the duration of clinical effectiveness of immunotargeted therapy in advanced or metastatic endometrial cancer: A pilot multicenter observational study

• Main Authors: A. A. Maltseva (Author), A. Yu. Kalinchuk (Author), N. V. Krakhmal (Author), N. M. Chernorubashkina (Author), E. S. Martynova (Author), R. A. Zukov (Author), A. A. Gofman (Author), A. B. Villert (Author), O. N. Churuksaeva (Author), L. A. Kolomiets (Author), L. A. Tashireva (Author)
• Format: Book
• Published: ABV-press, 2024-05-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Background. The inclusion of lenvatinib in the immunotherapy regimen for patients with MSS/pMMR endometrial cancer (EC) is due to its ability to modulate the tumor microenvironment, which allows the use of pembrolizumab in low-immunogenic tumors. However, only 30 % of patients with advanced or metas...